Retrospective Observational Study in Patients With Relapsed / Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed/Refractory
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically confirmed diagnosis of Primary Mediastinal B Cell Lymphoma Relapsed/Refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till Novembre 2021
• Age ≥ 18 years at enrollment
• Signature of written informed consent (where applicable)
Locations
Other Locations
Italy
Azienda Ospedaliera Universitaria- POLICLINICO BARI
RECRUITING
Bari
IRCCS Azienda Ospedaliero - Universitaria di Bologna
RECRUITING
Bologna
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITING
Milan
Contact Information
Primary
Pier Luigi Zinzani, MD
pierluigi.zinzani@unibo.it
+390512144042
Backup
Cinzia Pellegrini, MD
cinzia.pellegrini@aosp.bo.it
+390512143680
Time Frame
Start Date: 2022-04-23
Estimated Completion Date: 2025-12
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: IRCCS Azienda Ospedaliero-Universitaria di Bologna